<a href="https://www.fiercebiotech.com/medtech/foundation-medicine-boosts-bristol-myers-squibb-collab-new-diagnostic-target" hreflang="en">Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target</a>
Foundation Medicine is enhancing its collaboration with Bristol Myers Squibb to develop a diagnostic tool, FoundationOne CDx, aimed at identifying patients with homozygous MTAP deletion, a key biomarker found in 10-15% of cancers, to better target therapies. This partnership builds on their previous work together since 2017, focusing on predictive biomarkers in cancer treatment.
Foundation Medicine's collaboration with Bristol Myers Squibb to develop a diagnostic tool for identifying homozygous MTAP deletion in cancer patients is a significant advancement in precision medicine. As this deletion is present in 10% to 15% of all cancers, the ability to accurately detect it with FoundationOne CDx can enhance the targeting of therapies and improve patient outcomes, representing a valuable opportunity for investment and development in genomic diagnostics and targeted therapeutics.